

West Midlands Adult Cystic Fibrosis Centre

Experience Of The Effects Of Kaftrio® + Kalydeco® On Patients Within The Lung Transplant Programme



University Hospitals
Birmingham
NHS Foundation Trust

J.Hussey, C.Evans, R.Davies, N.Gilday, F.King, J.Whitehouse, N.Patel, L.Jones – West Midlands Adult Cystic Fibrosis Centre, University Hospitals Birmingham NHS Trust

West Midlands
Adult Cystic Fibrosis
Centre

Aim

- To evaluate the impact of Kaftrio®+ Kalydeco® on patients' health within our lung transplant programme.



Method

- We assessed patients listed for transplant and those under regular review with the transplant team.
- Objective measurements were:** ppFEV1, weight, IV antibiotic courses, hospital admissions and transplant status. These were measured 1 year pre and 1 year post Kaftrio®+ Kalydeco®.

Results - patients listed for transplant


Pre Kaftrio®+ Kalydeco®

- 7 patients
- 1 not eligible for Kaftrio®+ Kalydeco® as already had a transplant and waiting for re transplant
- Mean ppFEV1 25% (range 22% – 29%)
- Mean weight 50.4kg (range 44.6kg – 74kg)
- Hospital admissions varied from 0–6 (total 21)
- IV antibiotic courses varied from 0–6 (total 22)

Post Kaftrio®+ Kalydeco®

- 3/7 patients
- 4 patients suspended to regular review list
- Mean ppFEV1 31.6% (increase 6.6%)
- Mean weight 66.1kg (highest weight gain 15.6kg)
- Hospital admissions varied from 0–2 (Total 6)
- IV antibiotic courses varied from 0–3 (Total 9)

Listed for transplant



Results - patients under regular review


Pre Kaftrio®+ Kalydeco®

- 21 patients
- 1 patient not eligible for Kaftrio®+ Kalydeco®
- Mean ppFEV1 30.3% (range 15% – 44%)
- Mean weight 57.6kg (range 36.9kg – 90.7kg)
- Hospital admissions varied 0–6 (total 53)
- IV antibiotic courses varied 0–6 (total 64)

Post Kaftrio®+ Kalydeco®

- 6 patients
- 9 patients discharged
- 1 patient discharged and referred back
- 5 patients DNA/cancelled appointments
- Mean ppFEV1 42% (Increase 11.7%)
- Mean weight 66kg (highest weight gain 26.6kg)
- Hospital admissions varied 0–5 (total 14)
- IV antibiotic courses varied 0–4 (total 16)

Regular review



Conclusion

- After taking Kaftrio®+ Kalydeco® for 1 year, patients within the lung transplant programme demonstrated an improvement in ppFEV1, an increase in weight and a reduction in both hospital admissions and courses of IV antibiotics.
- Over 50% (4/7) of patients were suspended from the lung transplant list and placed under regular review.
- Over 70% (15/21) of patients under regular review were discharged or did not attend further appointments.
- This study demonstrates the benefit of Kaftrio®+ Kalydeco® in people with CF with advanced lung disease.



Building healthier lives